Larvol Delta - AltruBio-Announces-First-Patient-Dosed-in-Phase-1-Trial-of-NextGeneration-Immune-Checkpoint-Enhancer-ALTB268-for-the-Treatment-of-Ulcerative-Colitis

leiolizumab (ALTB-268) - AltruBio

https://www.globenewswire.com/news-release/2023/01/23/2593259/0/en/AltruBio-Announces-First-Patient-Dosed-in-Phase-1-Trial-of-Next-Generation-Immune-Checkpoint-Enhancer-ALTB-268-for-the-Treatment-of-Ulcerative-Colitis.html

Jan 23, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next